Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
Overview
Which drugmaker holds the better potential for your portfolio? Bristol Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) both face a decade of patent cliffs and shifting regulatory landscapes in the healthcare sector.
Bristol Myers Squibb focuses on specialized medicines for serious diseases like cancer, while Pfizer operates a massive global portfolio spanning vaccines and primary care. Both companies are navigating the post-pandemic era by acquiring new drug pipelines. Comparing these giants helps clarify which path offers the more attractive balance of risk and reward for investors.
Details
Bristol Myers Squibb focuses on discovering and developing innovative medicines for serious diseases, with leadership in oncology, hematology, and neuroscience among pharmaceutical stocks. The company distributes its products globally to major markets like the United States and China through wholesalers and specialty pharmacies. It also maintains strategic alliances with Ono, Zai Lab (NASDAQ:ZLAB), BioNTech (NASDAQ:BNTX), Johnson & Johnson (NYSE:JNJ), Zenas BioPharma (NASDAQ:ZBIO), and Merck (NYSE:MRK).
Source
Originally published at www.fool.com.